Entero Healthcare Q1 FY27: income up 38% YoY to Rs 1943.5 cr

Key takeaway from the board meeting

Entero Healthcare Solutions Limited said its Board of Directors approved the company’s unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board meeting was held on August 7, 2026. The results were released along with limited review reports that carried an unmodified opinion from the statutory auditors. Alongside the financial update, the company also disclosed corporate actions including committee changes and a new step-down subsidiary. The disclosures together give investors both the quarterly financial picture and the near-term governance and operating agenda.

Consolidated performance shows top-line momentum

For Q1 FY27, Entero reported consolidated total income of ₹1,943.50 crore for the quarter ended June 30, 2026. This compared with ₹1,403.82 crore in Q1 FY26, implying an about 38.44% year-on-year rise based on the figures cited. Consolidated profit after tax (PAT) for the quarter stood at ₹52.05 crore, up from ₹27.80 crore in Q1 FY26. The company’s consolidated total expenses in Q1 FY27 were ₹1,876.38 crore. Profit before exceptional items and tax at the consolidated level was reported at ₹67.12 crore, with tax expenses of ₹15.07 crore.

Standalone numbers remain smaller than consolidated

On a standalone basis, Entero Healthcare reported total income of ₹106.41 crore for the quarter ended June 30, 2026, compared with ₹78.93 crore in the previous quarter. Standalone total expenses were ₹101.81 crore. Standalone profit before exceptional items and tax was ₹4.61 crore, and tax expenses were ₹1.15 crore. Standalone profit for the period was ₹3.46 crore, consistent with the standalone PAT figure stated in the data snapshot. Standalone earnings per share (basic and diluted) for the quarter were ₹0.79.

Verified PAT versus the raw alert figure

The information provided notes a difference between a raw news alert and verified filings on consolidated net profit. The raw alert figure cited consolidated net profit of ₹38.2 crore versus ₹28 crore, while verified filings indicate consolidated PAT of ₹52.05 crore for Q1 FY27. In company-result coverage, this distinction matters because market commentary can sometimes circulate preliminary or mismatched numbers. Here, the filing-based PAT of ₹52.05 crore is the figure tied to the detailed consolidated financials shared in the same context.

Governance updates: committee reshuffle and AGM schedule

Entero said its core board committees have been reconstituted, including the Audit Committee and the Stakeholders Relationship Committee. The reconstitution will be effective August 25, 2026. Separately, the company scheduled its 8th Annual General Meeting for August 19, 2026, at 12:30 p.m. IST, to be held through video conferencing and other audio-visual means. These dates set a near-term calendar for governance actions after the quarterly results approval.

New step-down subsidiary to scale retail chemistry offering

The company incorporated a step-down subsidiary, Qurovia Lifesciences Private Limited, on July 25, 2026. The stated purpose was to enhance Entero’s retail chemistry and healthcare offerings and scale operations. The disclosure places the incorporation in late July 2026, shortly before the Q1 FY27 results approval. Investors typically track such structures because they can signal expansion plans or business-line consolidation under separate entities.

Trading window and earnings call details

Entero had earlier closed the trading window for designated persons and their immediate relatives from July 1, 2026. The company reiterated that the trading window would open 48 hours after the disclosure of the financial results. It also announced an earnings call scheduled for August 10, 2026 at 12:00 PM IST to discuss Q1 FY27 performance and operational updates. The call, filed under SEBI Regulation 30, is set to feature CEO Prabhat Agrawal and CFO Dr. Balakrishnan Natesan Kaushik.

FY26 context from the annual report

In its FY26 annual report, Entero reported consolidated revenue from operations of ₹6,591.21 crore, reflecting 29.35% year-on-year growth from ₹5,095.78 crore in FY25. The annual report attributed growth to 13.4% organic growth and a 16% inorganic contribution. Gross profit was reported at ₹680.38 crore, with gross margin at 10.32% after an improvement of 78 basis points. FY26 EBITDA was ₹265.96 crore, up 55.03% year-on-year, with EBITDA margin at 4.03%. FY26 PAT was ₹145.84 crore, rising 35.75%, and the report noted a one-time exceptional charge of ₹6.1 crore (net of tax) linked to implementation of the new Labour Code.

Key numbers at a glance

Timeline of disclosed events

Market impact and what investors will watch next

The Q1 FY27 filing highlights a strong consolidated income base of ₹1,943.50 crore and a consolidated PAT of ₹52.05 crore, while the standalone profit remains much smaller at ₹3.46 crore. From a market-information perspective, the company has also provided a near-term cadence of events: the trading window reopening protocol, the August 10 earnings call, and the August 19 AGM. The incorporation of Qurovia Lifesciences adds an operational thread that could come up in management commentary during the call. Separately, the committee reconstitution effective August 25 is a governance development that investors often track for oversight continuity.

Conclusion

Entero Healthcare Solutions entered Q1 FY27 with higher consolidated income and profit compared with the year-ago quarter, and the board has paired the results approval with governance and structure updates. The next confirmed touchpoints are the August 10, 2026 earnings call and the August 19, 2026 AGM, where stakeholders can seek more detail on performance drivers and the role of the newly incorporated step-down subsidiary.